FDA Updates Lumateperone Label With Relapse-Prevention Data

• by Kathryn Wighton

• April 29, 2026

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

• by Kathryn Wighton

• April 30, 2026

• 3 min

Exploring caregiver experiences with the altitudes digital mental health program: A thematic analysis

• by Kelsey Ludwig, Elizabeth Fraser, David Penn, Bryan Stiles, Hanna Campbell, Heidi Dittus, Rathisree Seenivasan, Jeongwoo Lee, Mario Alvarez-Jimenez, John Gleeson

• June 6, 2026

Artificial Intelligence Centrality in Psychotic Delusions and Violence Risk in Forensic Psychiatry: Retrospective Observational Study of Judicial Decisions

• by Alexandre Hudon, Chanel Pagé

• May 20, 2026